Have a personal or library account? Click to login
Can we predict the co-occurrence of nonalcoholic fatty liver disease and uric acid urolithiasis? Assessment of prevalence based on findings in preoperative computed tomography imaging Cover

Can we predict the co-occurrence of nonalcoholic fatty liver disease and uric acid urolithiasis? Assessment of prevalence based on findings in preoperative computed tomography imaging

Open Access
|Mar 2026

References

  1. Ahmed KA, Younis SN. Association of non-alcoholic fatty liver disease with urolithiasis Detected on non-contrast computed tomography. AMJ 2022;7:87-92. doi: 10.56056/amj.2022.183.
  2. Oral A, Sahin T, Turker F, Kocak E. Relationship between serum uric acid levels and nonalcoholic fatty liver disease in non-obese patients. Medicina (Kaunas) 2019;55(9):600. doi: 10.3390/medicina55090600.
  3. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021;18(4):223-38. doi: 10.1038/s41575-020-00381-6.
  4. Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. Non-alcoholic fatty liver disease and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome. Int J Environ Res Public Health 2019;16(18):3415. doi: 10.3390/ijerph16183415.
  5. Byrne CD, Targher G. Nonalcoholic fatty liver disease: a multisystem disease. J Hepatol 2015;62:S47-64. doi: 10.1016/j.jhep.2014.12.012.
  6. Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, et al. Liver biopsy in type 2 diabetes mellitus: steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12(6):e0178473. doi: 10.1371/journal.pone.0178473.
  7. Wagner CA. Etiopathogenic factors of urolithiasis. Factores Etiopatogénicos de La Urolitiasis. Arch Esp Urol 2021;74(1):16-23.
  8. Trinchieri A. Epidemiology of urolithiasis: an update. Clin Cases Miner Bone Metab 2008;5(2):101-06.
  9. Velázquez AM, Bentanachs R, Sala-Vila A, Lázaro I, Rodríguez-Morató J, Sánchez RM, et al. ChREBP-driven DNL and PNPLA3 expression induced by liquid fructose are essential in the production of fatty liver and hyper-triglyceridemia in a high-fat diet-fed rat model. Mol Nutr Food Res 2022;66(7):e2101115. doi: 10.1002/mnfr.202101115.
  10. Badillo FGL, Cala OLO, Campos SNV, Ibañez EDV. Relationship between urolithiasis and fatty liver disease: findings in computed tomography. Tomography 2020;6:1-4, doi: 10.18383/j.tom.2020.00020.
  11. García Marchiñena P, Billordo Peres N, Liyo J, Ocantos J, Gonzalez M, Jurado A, et al. Tomografía computada como predictor de composición y fragilidad de la litiasis urinaria al tratamiento con litotricia extracorporea por ondas de choque in vitro [CT scan as a predictor of composition and fragility of urinary lithiasis treated with extracorporeal shock wave lithotripsy in vitro ]. Arch Esp Urol 2009;62(3):215-22. doi: 10.4321/s0004-06142009000300007.
  12. Gücük A. Usefulness of Hounsfield unit and density in the assessment and treatment of urinary stones. World J Nephrol 2014;3:282. doi: 10.5527/wjn.v3.i4.282.
  13. Bohte AE, Van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011;21:87-97. doi: 10.1007/s00330-010-1905-5.
  14. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN Clinical Practice Guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64(2):319-34. doi: 10.1097/MPG.0000000000001482.
  15. López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 2010;25(1):49-59. doi: 10.1007/s00467-008-0960-5.
  16. Alelign T, Petros B. Kidney stone disease: an update on current concepts. Adv Urol 2018;2018:3068365. doi: 10.1155/2018/3068365.
  17. Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12:86-96. doi: 10.3909/riu0459.
  18. Qin S, Wang S, Wang X, Wang J. Non-alcoholic fatty liver disease and the risk of urolithiasis: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97(35):e12092. doi: 10.1097/MD.0000000000012092.
  19. Einollahi B, Naghii MR, Sepandi M. Association of nonalcoholic fatty liver disease (NAFLD) with urolithiasis. Endocr Regul 2013;47:27-32. doi: 10.4149/endo_2013_01_27.
  20. Besiroglu H, Otunctemur A, Ozbek E. The metabolic syndrome and urolithiasis: a systematic review and meta-analysis. Ren Fail 2015;37(1):1-6. doi: 10.3109/0886022X.2014.976133.
  21. Trinchieri A, Croppi E, Montanari E. Obesity and urolithiasis: evidence of regional influences. Urolithiasis 2017;45:271-8. doi: 10.1007/s00240-016-0908-3.
  22. Pérez-Gutiérrez OZ, Hernández-Rocha C, Candia-Balboa RA, Arrese MA, Benítez C, Brizuela-Alcántara DC, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann Hepatol 2013;12(1):416424.
  23. Morita M, Ishida N, Uchiyama K, Yamaguchi K, Itoh Y, Shichiri M, et al. Fatty liver induced by free radicals and lipid peroxidation. Free Radic Res 2012;46:758-65. doi: 10.3109/10715762.2012.677840.
  24. Wang Y, Zhou M, Lam KSL, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metab 2009;53:201-12. doi: 10.1590/s0004-27302009000200012.
  25. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol 2018;68(5):1063-75. doi: 10.1016/j.jhep.2018.01.019.
  26. Lima WG, Martins-Santos MES, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie 2015;116:17-23. doi: 10.1016/j. biochi.2015.06.025.
  27. Manish KC, Leslie SW. Uric acid nephrolithiasis continuing education activity. Treasure Island (FL): StatPearls Publishing; 2023.
  28. Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol 2014;27(3):241-5. doi: 10.1007/s40620-013-0034-z.
  29. Ma Q, Fang L, Su R, Ma L, Xie G, Cheng Y. Uric acid stones, clinical manifestations and therapeutic considerations. Postgrad Med J 2018;94(1114):458-62. doi: 10.1136/postgradmedj-2017-135332.
DOI: https://doi.org/10.21164/pomjlifesci.989 | Journal eISSN: 2719-6313 | Journal ISSN: 2450-4637
Language: English
Page range: 1 - 5
Published on: Mar 3, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Marta Jankowska, Jakub Kalembkiewicz, Marek Miśkiewicz, Kamila Durmała, Aleksandra Słojewska, Krystian Kaczmarek, Marcin Słojewski, published by Pomeranian Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.